Investors
Investors

Investor Relations

Second Quarter 2010 Results
7/29/10 4:15 PM ET

Overview

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action allows INTERCEPT treatment to inactivate both established transfusion threats, such as hepatitis, HIV, West Nile virus and bacteria, as well as emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development.

Investor Relations Contact

Lainie Corten
Director, Global Communications & Marketing
Phone: 925-288-6319
E-mail: ir@cerus.com

Stock Quote

NASDAQ GM : CERS
CERS NASD
Price 3.13
Change +0.13
Volume 246,146
52 Week High 3.71
52 Week Low 1.57
Sep 02 2010 04:00 PM Pricing delayed 20 minutes

Receive Email Alerts

Alerts are emailed to you whenever certain new company information is posted to this site.
Sign-up Now!